This trial is active, not recruiting.

Condition cardiovascular diseases
Treatment fenofibrate
Sponsor National Institute on Aging (NIA)
Start date October 2005
End date December 2009
Trial size 60 participants
Trial identifier NCT00627653, AG0093, ROI AG15466


The purpose of this study is to determine if treatment with a drug called fenofibrate, which is a PPAR-alpha agonist and controls how the heart metabolizes fats, will reverse the age-related decline in cardiac fat metabolism and mechanical function.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification pharmacokinetics/dynamics study
Intervention model single group assignment
Masking open label
Primary purpose basic science
fenofibrate Lofibra; TriCor
148mg daily for 30 days

Primary Outcomes

Shift in Myocardial substrate utilization in aging hearts
time frame: After the day-30 PET scan

Secondary Outcomes

Increased left ventricular function due to shift in substrate use in aging hearts
time frame: After the day-30 PET scan

Eligibility Criteria

Male or female participants from 21 years up to 75 years old.

Inclusion Criteria: - Aged 60-75 or 21-35 - Normal glucose tolerance test - Normal plasma fasting lipid panel (fasting total cholesterol less than 220 mg/dL) - Normal rest/stress echocardiogram - BMI (body mass index) less than 30 kg/m2 - Must be sedentary (active, but do not engage in regular exercise or jobs that require strenuous exertion) Exclusion Criteria: - Coronary artery disease - High blood pressure - Current smoker - Diabetes mellitus - Cardiovascular disease (signs and symptoms of any kind) - Pregnant or breastfeeding

Additional Information

Official title PET (Positron Emission Tomography) Detection of the Effects of Aging on the Human Heart (Aim #2 Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function)
Principal investigator Robert Gropler, MD
Description In older Americans, cardiovascular disease is the leading cause of death and disability. It has been shown recently that with aging the human heart exhibits a decline in myocardial fatty acid utilization (MFAU) and oxidation (MFAO) and that these metabolic changes are paralleled by a decline in mechanical function. It has also been shown that peroxisome proliferator activated receptor alpha (PPAR-alpha) activates the expression of the genes encoding enzymes involved in mitochondrial fatty acid transport and oxidation. There is both indirect and direct evidence that PPAR-alpha-mediated responses decrease with age. Consequently, we hypothesize that changes in fatty acid in the aging heart may be mediated, at least in part, via a decline in PPAR-alpha-mediated responses. Thus, administration of a PPAR-alpha agonist to older humans will result in a shift in cardiac fatty acid metabolism to that more closely seen in younger humans and this shift will be paralleled by an improvement in cardiac mechanical function. To prove or disprove this hypothesis, we will determine, in aged and young healthy volunteers, whether stimulation of PPAR-alpha using the partial agonist, fenofibrate, shifts myocardial substrate utilization by increasing MFAU and MFAO, and whether these changes are associated with an increase in left ventricular function. Study participants will have 4 clinic visits, each lasting approximately 5 hours.
Trial information was received from ClinicalTrials.gov and was last updated in February 2009.
Information provided to ClinicalTrials.gov by National Institute on Aging (NIA).